Precision oncology startup Syapse raises $30M in Series D funding round

Syapse raised $30 million in Series D funding, the San Francisco-based precision medicine startup announced Nov. 14.

Syapse aims to provide hospitals with actionable oncology insights through its point-of-care precision medicine software platform. The platform organizes and presents structured clinical and genomic data to match patients with targeted therapies based on treatment and outcome information from patients across the U.S.

The Series D round comprised funding from returning investors Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Safeguard Scientifics and Social Capital. New investors included Amgen Ventures, Medidata Solutions, Merck Global Health Innovation Fund and Roche Venture Fund.

More articles on data analytics & precision medicine:
NIH taps 14 medical societies, community groups to recruit 'All of Us' participants
Study: 5 health indicators predict cardiovascular risk
Researchers analyze DNA from 'supercentenarians' aged 110+ to discover secret to longevity

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers